Renal Cell Carcinoma Diagnostics
Advertisement
Kidney injury molecule-1 is a transmembrane protein that can serve as a urinary indicator of acute renal tubular injury.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Drs. Joyce and Khanna examine the utility of a deep learning algorithm for automated renal volume calculation.
Drs. Joyce and Pierorazio weigh appropriate surveillance versus primary intervention for clinical T1a kidney tumors.
A new study by an international research team has identified new susceptibility regions associated with RCC development risk.
We spoke with several researchers involved in exploring the clinical utility of liquid biopsy for genitourinary cancers.
Dr. Wei helped uncover genetic, transcriptional, and immune differences in TFE3-rearranged RCC versus papillary, ccRCC.
A new study on the prognostic value of perinephric fat, renal sinus fat, and renal vein invasion in patients with pT3a RCC.
Targeted gene panel testing can serve as an option for patients if syndromic features are present.
Researchers sought to identify the frequency of germline mutations in patients 46 years or younger.
Researchers evaluated biomarkers to determine their prognostic potential for determining treatment modality for ccRCC.
Patients with early-onset RCC underwent genetic testing more often than those with bilateral RCC.
A Merit Award-winning abstract offered insight into differences in RCC susceptibility and implications for genetic screening.
Certain risk factors can result in pathological upstaging in patients treated with nephrectomy for nonmetastatic RCC.
Dr. Calais describes a novel radiotracer and explains how the recent data on this radiotracer further support its use.
To identify positive surgical margins, researchers used DESI-MSI to to distinguish normal tissue from RCC tissue samples.
Drs. McKay and Braun highlights novel RCC biomarkers being developed, including imaging-, pathology-, and blood-based ones.
Dr. McKay speaks with Dr. Braun on the current biomarker landscape for RCC and how biomarkers have shaped treatment.
Tumors with only a VHL mutation were associated with better outcomes compared with tumors containing additional mutations.
Plasma and urine free glycosaminoglycan profiles—or GAGomes—can potentially be used as metabolic biomarkers for mRCC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.